| Biomarker ID | 1563 |
| PMID | 31069142 |
| Year | 2019 |
| Biomarker | WISP1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with increasing Stage |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: Wnt signaling pathway |
| Experiment | pTNM 2 Vs pTNM 3 Vs pTNM 4 |
| Type of Biomarker | Prognostic |
| Cohort | immunofluorescence dataset with 285 samples with prostate adenocarcinoma were chosen. 201 with stage pTNM 2, 73 with pTNM 3 and 9 with pTNM 4 were present |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Immunofluorescence |
| Clinical | No |
| Remarks | Expression was measured as Mean fluorescence intensity |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |